Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Down 5.1% After Insider Selling

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s share price dropped 5.1% on Tuesday following insider selling activity. The stock traded as low as $10.79 and last traded at $10.7450. Approximately 128,543 shares changed hands during trading, a decline of 90% from the average session volume of 1,252,757 shares. The stock had previously closed at $11.32.

Specifically, CEO Neil McFarlane sold 20,000 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer owned 417,225 shares in the company, valued at approximately $4,693,781.25. This represents a 4.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZVRA. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Citizens Jmp boosted their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. BTIG Research reduced their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $27.14.

Zevra Therapeutics Stock Down 1.5%

The business’s 50-day moving average price is $11.53 and its 200-day moving average price is $11.41. The firm has a market capitalization of $607.46 million, a PE ratio of 6.58 and a beta of 0.98.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. On average, analysts anticipate that Zevra Therapeutics, Inc. will post 0.72 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new position in Zevra Therapeutics during the second quarter valued at approximately $28,000. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in Zevra Therapeutics in the fourth quarter worth approximately $53,000. DGS Capital Management LLC bought a new stake in Zevra Therapeutics in the fourth quarter worth approximately $133,000. Tidal Investments LLC bought a new stake in Zevra Therapeutics in the second quarter worth approximately $150,000. Finally, Quantinno Capital Management LP increased its stake in shares of Zevra Therapeutics by 114.1% during the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after purchasing an additional 17,065 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.